Description: Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Home Page: www.oncotelic.com
29397 Agoura Road
Agoura Hills,
CA
91301
United States
Phone:
650 635 7000
Officers
| Name | Title |
|---|---|
| Dr. Vuong Trieu Ph.D. | Chairman & CEO |
| Mr. Amit Shah | Chief Financial Officer |
| Dr. Chulho Park Ph.D. | Consultant |
| Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. | Chief Clinical Officer of Translational Medicine & Director |
| Mr. Saranjit Saund | CBO & GM of AI Division |
| Dr. Larn Hwang | Chief Scientific Officer |
| Dr. Fatih M. Uckun M.D., Ph.D. | Chief Medical Officer |
| Dr. Seymour Howard Fein M.D. | Chief Regulatory Officer |
| Mr. Burcak Beser | CTO of AI Division |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 4.0258 |
|---|---|
| Trailing PE: | 2.95 |
| Price-to-Book MRQ: | 0.8894 |
| Price-to-Sales TTM: | 8.396 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |